Loading...

Telix Pharmaceuticals Limited

TLX.AXASX
Healthcare
Biotechnology
A$18.33
A$1.41(8.33%)

Telix Pharmaceuticals Limited (TLX.AX) Financial Performance & Income Statement Overview

Analyze Telix Pharmaceuticals Limited (TLX.AX) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.

Revenue Growth
55.85%
55.85%
Operating Income Growth
58.29%
58.29%
Net Income Growth
857.95%
857.95%
Operating Cash Flow Growth
80.16%
80.16%
Operating Margin
10.49%
10.49%
Gross Margin
65.08%
65.08%
Net Profit Margin
6.37%
6.37%
ROE
10.27%
10.27%
ROIC
6.93%
6.93%

Telix Pharmaceuticals Limited (TLX.AX) Income Statement & Financial Overview

Analyze Telix Pharmaceuticals Limited’s TLX.AX earnings with segmented quarterly and yearly financial statement figures.

MetricQ4 2024Q2 2024Q4 2023Q2 2023
Revenue$594.24M$188.96M$281.71M$220.83M
Cost of Revenue$208.45M$65.08M$57.74M$130.02M
Gross Profit$385.80M$123.88M$223.97M$90.81M
Gross Profit Ratio$0.65$0.66$0.80$0.41
R&D Expenses$148.85M$45.78M$98.40M$30.45M
SG&A Expenses$168.61M$64.25M$105.50M$28.93M
Operating Expenses$317.42M$110.13M$203.90M$59.37M
Total Costs & Expenses$525.87M$175.21M$261.64M$189.40M
Interest Income$10.25M$610000.00$566000.00$453000.00
Interest Expense$31.55M$4.94M$548000.00$442000.00
Depreciation & Amortization-$2.00M$2.00M$3.64M$3.29M
EBITDA$76.80M$15.75M$23.71M$34.72M
EBITDA Ratio$0.13$0.08$0.08$0.16
Operating Income$68.38M$13.75M$20.07M$31.44M
Operating Income Ratio$0.12$0.07$0.07$0.14
Other Income/Expenses (Net)-$21.46M-$4.61M-$4.69M-$43.74M
Income Before Tax$46.91M$9.14M$15.39M-$12.30M
Income Before Tax Ratio$0.08$0.05$0.05-$0.06
Income Tax Expense$8.67M-$2.54M-$4.14M$2.02M
Net Income$38.24M$11.68M$19.53M-$14.32M
Net Income Ratio$0.06$0.06$0.07-$0.06
EPS$0.12$0.03$0.06-$0.05
Diluted EPS$0.11$0.03$0.06-$0.05
Weighted Avg Shares Outstanding$331.23M$334.23M$323.73M$317.62M
Weighted Avg Shares Outstanding (Diluted)$345.19M$350.75M$323.73M$317.62M

The company's financials show resilient growth, with revenue advancing from $220.83M in Q2 2023 to $594.24M in Q4 2024. Gross profit remained healthy with margins at 65% in Q4 2024 compared to 41% in Q2 2023. Operating income hit $68.38M last quarter, sustaining a consistent 12% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $76.80M. Net income rose to $38.24M, while earnings per share reached $0.12. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;